Abstract
Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Current Pharmaceutical Design
Title: The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells
Volume: 10 Issue: 17
Author(s): L. Amati, R. Cozzolongo, O. G. Manghisi, R. Cuppone, N. M. Pellegrino, D. Caccavo and E. Jirillo
Affiliation:
Keywords: hepatitis c virus, interferon-a, ribavirin, b iymphocytes, endotoxins
Abstract: Previous data demonstrated that an elevated percentage of hepatitis C virus (HCV) infected patients are endotoxemic. Endotoxemic patients are poor responders to the interferon (IFN)- α / ribavirin (RIB) treatment and exhibit lower serum levels of IFN-γ and interleukin (IL)-10 than the responder counterpart. Here we provide evidence that in endotoxemic HCV+ patients absolute numbers of CD19+ cells (B cells) are higher than those observed in the non-endotoxemic counterpart at the end of the combined treatment. Moreover, anti lactoferrin (LF) antibodies are more elevated in non-responder HCV+ patients than in the responders. In turn, these autoantibodies may affect the antiviral activity of LF, on the one hand , and, on the other hand abrogate the LF binding to lipopolysaccharides (LPS). Such an interaction hampers the binding of LPS to LPS binding protein, thus inhibiting LPS fixation to CD14+ cells and, ultimately, leading to a decreased release of proinflammatory cytokines.
Export Options
About this article
Cite this article as:
Amati L., Cozzolongo R., Manghisi G. O., Cuppone R., Pellegrino M. N., Caccavo D. and Jirillo E., The Immune Responsiveness in Hepatitis C Virus Infected Patients: Effects of Interferon-Alfa / Ribavirin Combined Treatment on the Lymphocyte Response with Special Reference to B Cells, Current Pharmaceutical Design 2004; 10 (17) . https://dx.doi.org/10.2174/1381612043384231
DOI https://dx.doi.org/10.2174/1381612043384231 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of L-Glucose in Cancer Diagnosis: Results from In Vitro and In Vivo Studies
Current Medicinal Chemistry In Vivo Optical Imaging in Gene & Cell Therapy
Current Gene Therapy The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Heme Oxygenase-1 in Lung Disease
Current Drug Targets MicroRNA-21 as Therapeutic Target in Cancer and Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Recent Patents on Mesenchymal Stem Cell Mediated Therapy in Inflammatory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Disorder in Milk Proteins: α-Lactalbumin. Part B. A Multifunctional Whey Protein Acting as an Oligomeric Molten Globular “Oil Container” in the Anti-Tumorigenic Drugs, Liprotides
Current Protein & Peptide Science Xenobiotic Sulphation and its Variability During Inflammation: a Factor in Adverse Drug Reactions?
Current Drug Metabolism Cell Penetrating Peptides for In Vivo Molecular Imaging Applications
Current Pharmaceutical Design Bcl-2 Antisense in the Treatment of Human Malignancies: A Delusion in Targeted Therapy
Current Pharmaceutical Biotechnology Pyrimidine Nucleosides in Molecular PET Imaging of Tumor Proliferation
Current Medicinal Chemistry Predicating Candidate Cancer-Associated Genes in the Human Signaling Network Using Centrality
Current Bioinformatics Prospects of Nanocarriers for Oral Delivery of Bioactives Using Targeting Strategies
Current Pharmaceutical Biotechnology Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment
Current Drug Targets Current Advances in the Synthesis and Antitumoral Activity of SIRT1-2 Inhibitors by Modulation of p53 and Pro-Apoptotic Proteins
Current Medicinal Chemistry Resveratrol, a Phytochemical Inducer of Multiple Cell Death Pathways: Apoptosis, Autophagy and Mitotic Catastrophe
Current Medicinal Chemistry Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets Synthetic Lethality and PARP-Inhibitors in Oral and Head & Neck Cancer
Current Pharmaceutical Design Distribution, Bioactivities and Therapeutical Potentials of Pentagalloylglucopyranose
Current Bioactive Compounds